

Serial No. to be assigned  
Filed: concurrently herewith  
Page 3

### REMARKS

Claims 1-12 are pending in the above application. Claims 4-5 have been amended to better conform to U.S. practice, and Claims 8-13 have been amended for the purposes of renumbering. Applicants respectfully request substantive examination on the merits.

Respectfully submitted,



Robert J. Smith  
Attorney for Applicants  
Registration No. 40,820



20792


PATENT TRADEMARK OFFICE

### CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number EL733097607US

Date of Deposit: July 19, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, DC 20231.

  
Keowanna V.C. Best

Date : July 19, 2001

**Version With Markings To Show Changes Made**

4. (Amended) A Method according **[to any preceding claim]** claim 1 wherein the solid porous particles are kieselguhr or perlite particles or mixtures thereof.

5. (Amended) A method according to **[any of claims 1 to 3]** claim 1 wherein the sold porous particles are diatomaceous earth particles.

**[8.] 7.** (Amended) A method according to claim 1 wherein the pore size is in the range 0.6 to 6 microns.

**[9.] 8.** (Amended) A method according to claim 1 wherein the pore size is in the range 0.6 to 1.5 microns.

**[10.] 9.** (Amended) A method according to claim 1 wherein the depth filter has a thickness of 2 to 5 mm.

**[11.] 10.** (Amended) A method according to Claim 1 wherein the natural product is a protein.

**[12.] 11.** (Amended) A method according to claim 1 wherein the aqueous liquid comprises a blood plasma product.

**[13.] 12.** ( Amended) A method according to **[claim 12]** claim 11 wherein the blood plasma product is selected from the group consisting of albumin, an immunoglobulin, Factor IX, thrombin, fibronectin, fibrinogen, Factor VIII, Factor II, Factor VII, Factor IX, **[or]** and Factor X.